西罗莫司如何购买？

Tetracene macrolides are potentially new and potent immunosuppressants with less toxicity discovered so far, providing a new treatment alternative for transplant recipients. Sirolimus is a macrolide antibiotic that is used long-term to help improve disease. So, how to buy Sirolimus from Biocon India?

The original drug sirolimus is produced by Pfizer. Although the original drug has been on the market in China for many years, the price of the original drug is usually relatively high, while the sirolimus produced by India's Biocon is relatively cheap. The current specification of Biocon Sirolimus in India is 1 mg x 10 tablets, and the price is around $200. Patients in need can purchase it abroad, or obtain the drug through domestic professional overseas medical service organizations (such as Medical Companion Travel), and have it delivered directly to their homes, ensuring authenticity.

Biocon is one of India's three largest biotech companies and an emerging global biopharmaceutical company that is committed to reducing the cost of treatment for chronic diseases such as diabetes, cancer and autoimmune disease patients by leveraging India's cost advantages and partners to provide affordable healthcare solutions to healthcare systems around the world.

Sirolimus is suitable for patients 13 years of age or older who have received kidney transplants to prevent organ rejection. Recommended for use in combination with cyclosporine and corticosteroids. For patients who receive a kidney transplant, rejection after surgery is what everyone is most worried about. This may mean that the surgical treatment fails and the patient cannot survive long-term. The use of sirolimus can effectively reduce the failure rate after transplantation.

Experimental studies have found that it does not inhibit calcineurin after binding to cytoplasmic proteins, so it can completely avoid the nephrotoxicity of calcineurin inhibitors (CNI). It is one of the best choices when liver or renal insufficiency occurs after organ transplantation or when CNI cannot reach the ideal drug concentration.